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Enhanced neuronal Met signalling levels in ALS mice
delay disease onset
M Genestine1,5, E Caricati1,4,5, A Fico1,5, S Richelme1, H Hassani1, C Sunyach2, F Lamballe1, GC Panzica3, B Pettmann2,
F Helmbacher1, C Raoul2, F Maina*,1,6 and R Dono*,1,6
Signalling by receptor tyrosine kinases (RTKs) coordinates basic cellular processes during development and in adulthood.
Whereas aberrant RTK signalling can lead to cancer, reactivation of RTKs is often found following stress or cell damage. This has
led to the common belief that RTKs can counteract degenerative processes and so strategies to exploit them for therapy have
been extensively explored. An understanding of how RTK stimuli act at cellular levels is needed, however, to evaluate their
mechanism of therapeutic action. In this study, we genetically explored the biological and functional significance of enhanced
signalling by the Met RTK in neurons, in the context of a neurodegenerative disease. Conditional met-transgenic mice, namely
Rosa26LacZstopMet, have been engineered to trigger increased Met signalling in a temporal and tissue-specific regulated
manner. Enhancing Met levels in neurons does not affect either motor neuron (MN) development or maintenance. In contrast,
increased neuronal Met in amyotrophic lateral sclerosis (ALS) mice prolongs life span, retards MN loss, and ameliorates motor
performance, by selectively delaying disease onset. Thus, our studies highlight the properties of RTKs to counteract toxic
signals in a disease characterized by dysfunction of multiple cell types by acting in MNs. Moreover, they emphasize the
relevance of genetically assessing the effectiveness of agents targeting neurons during ALS evolution.
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Signalling by receptor tyrosine kinases (RTKs) is involved in
cell communication events regulating tissue morphogenesis
during development and tissue homeostasis during adult-
hood.1 In vivo, RTK signalling levels vary according to a
number of parameters, such as RTK expression levels, ligand
availability, action of positive/negative signalling regulators,
and components of the signalling cascade. The levels of RTK
signalling determine qualitatively different biological out-
comes.2 Given the multiple roles of RTKs in coordinating
basic biological processes, modulating their activation levels
is a means of achieving different cellular responses in normal
processes and in pathological conditions. Notably, RTK
activation is tightly regulated in healthy adult tissues as
aberrant signalling in susceptible cells can cause pathologies,
such as cancer.1,3 Conversely, studies on degenerative
diseases have shown that following stress or cell damage
there is nearly always a reactivation of RTK signalling,
coinciding with periods of active fight for survival/repair.4,5
For example, genetic analysis of RTK functions in neurode-
generative processes have demonstrated their requirement
for repair of damaged tissues.4 In contrast, studies on cultured
cells and on animal models have shown that symptoms linked
to degenerative diseases can be ameliorated when activation
of appropriate RTKs is achieved through exogenous ligand
administration.4,6 However, it is still not clear to which extent
levels of remobilized endogenous RTKs are limiting for
effective neuronal repair in disease CNS.
Over the last years, a regional and temporal map of RTK-
dependency has emerged, suggesting that an appropriate
enhancement of RTK signalling might be beneficial to
efficiently counteract disease onset and progression. This
issue is particularly relevant for neurodegenerative diseases,
such as amyotrophic lateral sclerosis (ALS), an adult onset
motor neuron (MN) disease caused by pathological processes
occurring in both neuronal and non-neuronal cells.7 ALS
involves progressive degeneration of upper and lower MNs,
culminating in muscle wasting, and death mostly due to
respiratory failure. Although the aetiology of most cases
remains unknown, 10–20% of familial ALS is caused by
mutations in the superoxide dismutase1 (SOD1) gene.
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Consistently, transgenic mice expressing the mutant forms
of human SOD1 recapitulate a number of ALS symptoms
and have been instrumental in evaluating the molecular
and cellular events underlying ALS pathology.7 Moreover,
genetic and cell biological studies based on the differential
expression of mutant SOD1 in distinct cell types have
demonstrated that although death of MNs causes ALS
symptoms, the disease also renders other cells, such as
astrocytes and microglia, dysfunctional. Thus, MN loss, in
addition to a cell-autonomous origin, is also triggered by non-
cell-autonomous defects involving toxicity of other unhealthy
cells.8,9 Notably, these different cell types play distinct roles in
ALS pathogenesis. Damage within MNs is primarily asso-
ciated with disease onset and its early progression phase,
whereas damage within microglia and astrocytes accelerates
MN degeneration and ALS progression.8–12 The recognition
that multiple cell types determine ALS evolution has boosted
the need to understand the relative contribution of providing
beneficial signals to different cell types involved in the
disease.
Among several strategies to alleviate ALS symptoms, a
major hope has been placed on the ability of trophic factors,
acting on MN in culture or during development,4,7 to activate
endogenous RTKs. Initial results were disappointing as
infusion of specific trophic factors had little or no beneficial
effects. The weakness of these approaches appeared to be
inadequate delivery of these factors to the right cells. This
possibility was further supported by genetic studies assessing
growth factor efficacy depending on the delivery site.13,14
Therefore, understanding the relative contribution of enhan-
cing RTK signalling in distinct cell types is needed to further
clarify the ALS biology and to evaluate how beneficial signals
should be delivered for therapy.
In this study, we assessed the biological and functional
significance of enhanced signalling, above endogenous
levels, downstream of the Met RTK specifically in neurons
during neuro-degenerative diseases, such as ALS. A number
of features makes the Met receptor of special interest to
address RTK signalling levels during neuro-degenera-
tion.15,16 During development, activation of the Met receptor
by its ligand HGF regulates MN fate at multiple levels,
including identity acquisition, axonal growth, and survival.2,17–20
During injury, HGF is able to enhance regeneration of the
lesioned spinal cord and of crushed peripheral nerves.21,22
Intracerebral delivery or transgenic-mediated neuronal
expression of HGF in mutant SOD1 animal models acts
simultaneously on different dysfunctional cell types.23,24
However, the contribution of enhancing Met signalling
uniquely in neurons and its relative impact on ALS
onset and progression remains to be established. To enhance
Met signalling above a threshold level in a temporal
and tissue-specific manner, we generated conditional met
transgenic mice using the cre-loxP system. Here, we show
that transgene-mediated neuronal expression of the Met RTK
in SOD1G93A mice selectively delays disease onset,
without slowing down its progression. Our findings show that
boosting RTK signalling in a cell-type-restricted manner can
have a distinct beneficial impact in counteracting the
processes underlying the evolution of neurodegenerative
diseases.
Results
Generation of conditional Rosa26LacZstopMet
transgenic mice. To enhance Met signalling levels in a
temporally and spatially regulated manner, we generated
mice carrying a conditional mouse–human chimeric met
transgene (met tg). In particular, we engineered a mouse
strain in which a cytomegalovirus (CMV)-enhancer/b-actin-
promoter controls the expression of a floxed-b-geo-reporter
gene followed by a met tg. Such a strategy was chosen to
keep the met tg silent, unless the stop cassette is excised by
cre-mediated recombination. To avoid integration site effects
and favour loxP-site accessibility, the construct was inserted
into the Rosa26 locus (Rosa26LacZstopMet, referred to
R26LacZstopMet; Figures 1a–c).
To specifically gain expression in neural cells, we crossed
the R26LacZstopMet mice with the nestin-cre transgenics25
(nestin-cre;Rosa26LacZstopMet, referred to as Nes-R26Met),
leading to the excision of the lacZ-floxed cassette and
consequently expression of the Met chimeric protein (Mettg)
in neural tissues (Figures 1c and d). Western blot analysis of
E15.5 embryos and P7mice revealed the presence of Mettg in
dissected brains and spinal cords only after recombination
(Figure 1d). To estimate Mettg levels versus endogenous Met,
we performed western blot analysis of brain and spinal cord
protein extracts at different developmental stages using
antibodies recognizing the kinase domain of both endogenous
and Mettg. Quantification analyses indicated that Mettg levels
were at least 5/7-fold increased in brains and spinal cords of
heterozygous Nes-R26Met, when compared with endogenous
mouse Met (Figures 1e and f). Consistently, Mettg levels were
twofold higher in homozygous mice compared to hetero-
zygous littermates (Figures 1d–f).
We next characterized the R26LacZstopMet mice before
and after recombination by following the expression of the
lacZ-stop cassette and met tg transcript in adult brains and
spinal cords. We found a decrease in b-galactosidase activity
and lacZ transcripts in Nes-R26Met compared with R26 LacZ-
stopMet transgenics, indicating that recombination in several
brain regions occurred as expected (Figures 2a–d, Supple-
mentary Figures 1 and 2). Conversely, mettg was expressed
in brains only after recombination in a pattern complementary
to lacZ distribution (Figures 2e and f). High levels were found
in the hippocampus, cerebellum, cerebral cortex, and cervical
spinal cord (Figures 2g–i). Expression studies performed
on adult lumbar spinal cord sections revealed also a
complementary distribution pattern. In particular, lacZ or
mettg were found in cells with large nuclei resembling MNs
of R26LacZstopMet and Nes-R26Met, respectively (Figure 3).
Quantification analysis revealed that cre-mediated excision
occurred in approximately 56% of these cells (56.3±1.1;
Po0.0001; Figure 3g).
Molecular and cellular characterization of Nes-R26Met
mice. Although the Rosa26 locus drives gene expression
ubiquitously,26 we observed that the lacZ distribution in
brains and spinal cords of adult R26LacZstopMet mice
appeared restricted to distinct cell types (Figures 2a–d
and 3a–f, Supplementary Figures 1 and 2). Colocalization
studies revealed b-galactosidase activity predominantly in
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NeuN-positive neurons, but not in glial fibrillary acidic protein
(GFAP)-positive astrocytes (Figures 4a–h). The restricted
neuronal lacZ expression was also observed in cultured cells
(Figures 4i–n). Thus, the genetic setting we adopted (CMV-
enhancer/b-actin-promoter in Rosa26) results in an animal
model with a restricted expression of the transgene,
indicating that mettg should be predominantly confined
to neurons after nestin-cre-mediated recombination. Consis-
tently, mettg transcripts colocalized with Smi32-positive
neurons, but not with GFAP-positive astrocytes (Supple-
mentary Figure 3). The restricted expression of mettg in
neurons was also observed in Nes-R26Met adult spinal cords,
Figure 1 Temporal and tissue-specific Met transgene activation using Cre-mediated recombination. (a) The R26LacZstopMet construct targeted in the Rosa26 locus is
shown. The targeting construct consists of the CMV-enhancer and the chicken b-actin promoter (CMV/b-actin) driving the b-geo reporter and a Met chimeric cDNA. The
reporter gene is followed by three copies of the SV40 polyadenylation signal (3xpA) and flanked by loxP sites. The Met chimeric cDNA consists of a 50 portion encoding the
mouse extracellular domain fused to a 30 region coding for the intracellular human portion. Positions of the probes used for Southern analysis (a and b) as well as primers used
for PCR (1, 2, 3) are indicated. (b) Southern blots of neo-resistant ES clones analyzed with probe a (EcoRI digestion; top) and probe b (EcoRV digestion; bottom). The 15.5 Kb
band corresponds to the wild-type allele whereas the 5.5 Kb band depicts the recombinant allele in clones 1 and 2. (c) PCR of mouse-tail genomic DNAs showing the mutant
allele before and after Cre recombination (top). The presence of an amplicon in the Nes-R26Met mice with the 1þ 2 primers is detected because genotypes are performed
using DNA extracted from tails, which include tissues with and without recombination. PCR showing the genotypes of heterozygous and homozygous Nes-R26Met mice
(bottom). (d) Western blots showing the expression of the Met chimeric protein (using anti-human Met antibodies) in brain and spinal cord extracts from embryos (E15.5) and
newborn mice (P7) with the indicated genotypes. (e) Quantification analysis of Met chimeric protein levels versus endogenous Met. Western blot analysis of protein extracts
from dissected brains and spinal cords at different developmental stages using antibodies recognizing the Met kinase domain (MetKD). (f) Quantification analyses revealed
that levels of Met chimeric proteins were at least five- and sevenfolds increased in brains and spinal cords of heterozygous Nes-R26Met, respectively, when compared with
the endogenous mouse Met. Met chimeric levels were double in homozygous mice. Numbers on columns indicate fold of increase in Met protein levels over the endogenous
Met. In the graph, Nes-R26Met and Nes-R26Met/Met genotypes are indicated as M/þ and M/M, respectively. Values are expressed as means±S.E.M. Tub, tubulin; hMet,
human-Met
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where it was found in dorsal horn neurons, intermediate
lateral neurons, and MNs, but not in GFAP-positive astro-
cytes (Figure 5). Thus, mettg is predominantly restricted to
neurons in Nes-R26Met mice.
We next examined whether Mettg protein was active by
following its phosphorylation state using anti-phospho-Met
antibodies. High levels of phosphorylated Mettg were found in
the pons, medulla, lateral ventricles, rostral-migratory stream,
olfactory bulbs, cerebral and lumbar spinal cords (Figure 6
and data not shown). These results show that Mettg is
predominantly functional in spatially restricted domains, which
possibly correlate to a map of cellular competence for Mettg
activation influenced by a combination of parameters, such
as environmental contexts (e.g., endogenous HGF levels)
or permissive intracellular mechanisms (e.g., signalling
modulators). Altogether these data show that Nes-R26Met
mice can be a useful animal model to investigate the
functional consequences of enhancing Met levels in distinct
cell types, using available tissue-specific cre-lines.
Phenotypical characterization of Nes-R26Met mice. As
previously discussed, Met regulates specification, axonal
growth, and survival of MN subtypes during development.17–20
We therefore evaluated whether enhanced Met levels
influence MN numbers in Nes-R26Met mice. By staining
spinal cord sections either with cresyl violet or with vesicular-
acetylcholie-transporter (VAChT) antibodies, similar MN
numbers were found at thoracic (data not shown) or lumbar
spinal cord levels in Nes-R26Met and control animals
(P40.05; Figures 7a–d and g). As expected by the
Figure 2 Molecular characterization of Nes-R26Met and R26LacZstopMet mice in adult brains. (a–d) Expression of the lacZ reporter gene was followed by measuring
b-galactosidase (X-Gal) activity (a and b) or its transcript levels (c and d) on sagittal sections. Decrease in X-Gal and lacZ transcripts were found after nestin-cre-mediated
recombination. (e and f) Expression of the met chimeric transgene in sagittal section of adult Nes-R26Met and R26LacZstopMet brains. (g–i) High levels of transgenic met
transcripts were detected in the hippocampus (g), cerebellum (h), cervical spinal cord (i). Panels (g–i) show enlarged views of brain areas delineated by the rectangles in (e).
cb, cerebellum; cc, cerebral cortex; h, hippocampus; sc, spinal cord
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colocalization studies, no differences in GFAP-fluorescence
intensity were observed (P40.05; Figures 7e, f and h).
As body weight is a generic indicator of animal physiology
influenced by body metabolism, activity, and feeding beha-
viour, the weight of Nes-R26Met mice was followed over-time
and no significant differences were found versus controls
(P40.05; Figure 7j). We next performed the rotarod test to
evaluate the overall motor function and no significant
differences were found in Nes-R26Met versus controls
(P40.05; Figure 7i). Altogether, these studies show that
enhancing Met levels in neurons does not cause gross
physiological abnormalities.
Neuronal-enhanced Met levels counteract ALS
symptoms in SOD transgenic mice. We next
investigated the functional relevance of genetically
enhancing Met signalling levels in the context of a
neurodegenerative disorder, such as the ALS. The
Nes-R26Met mice were therefore crossed with a strain
carrying high copy numbers of the SOD1G93A transgene to
generate an ALS animal model with increased Met levels in
neurons. Five groups of mice were generated: (a) wild-type;
(b) Rosa26 LacZstopMet, (c) Nes-R26Met, (d) SOD1G93A
(referred to as SOD), and (e) Nes-R26Met;SOD1G93A
(referred to as Nes-R26Met-SOD). As no significant
changes were observed between wild-type,
Rosa26 LacZstopMet, and Nes-R26Met for all parameters
examined, results of control animals included these three
groups.
By evaluating the life span of SOD and Nes-R26Met-SOD
mice, we found that neuronal-enhanced Met levels prolonged
the survival by 13 days (mean age, SOD: 136±2 days;
Nes-R26Met-SOD: 149±3 days; P¼ 0.0021; Figure 8a). As
reduction of body weight is an objective measure of ALS
disease, we examined its evolution in SOD and Nes-R26Met-
SOD mice, and found that neuronal-enhanced Met levels
delayed body weight loss. In particular, loss of 10% body
weight was retarded for 13 days (SOD: 123±3 days; Nes-
R26Met-SOD: 136±5 days; P¼ 0.0094; Figure 8b), whereas
no significant differences were observed during disease
progression (SOD: 12.9±2.5 days; Nes-R26Met-SOD:
13±2.4 days; P40.05; Figure 8c). Together, these results
indicate that enhanced Met levels in neurons counteract ALS
symptoms in SOD transgenic mice.
Improved motor performance and delayed onset of
paralysis in SOD mice with neuronal-enhanced Met
levels. The neuro-degeneration defects causing ALS
disease lead to progressive muscle weakness, atrophy,
and paralysis. Screwed hindlimbs and locomotor defects are
among the first symptoms affecting transgenic ALS mice. We
Figure 3 Molecular analysis of Nes-R26Met and R26LacZstopMet mice in adult
lumbar spinal cords on transversal sections. (a and b) In situ hybridization using lacZ
riboprobes. (c and d) Enlarged view of the ventral regions, showing lacZ expression in
distinct cell types characterized by large cell nuclei resembling MNs in R26LacZstopMet
and a decrease in its levels after nestin-cre-mediated recombination in Nes-R26Met.
(e and f) Section showing the overlap of X-Gal activity and DAPI staining in lumbar
spinal cords. X-Gal-negative cells with large nuclei were predominantly found in
Nes-R26Met, but not in R26LacZstopMet transgenics. Arrows and arrowheads points to
X-Gal-negative and X-Gal-positive cells with large nuclei, respectively. (g) Quantification
analysis of X-Gal-positive (blue) and X-Gal-negative cells with large nuclei (resembling
MNs; white) in Nes-R26Met mice, showing that nestin-cre-mediated lacZ excision
occurred in approximately 56% of these cells. Values are expressed as means±S.E.M.
(h–k) Expression of the met chimeric transgene in lumbar spinal cords. Panels (j and k)
show an enlarged view of ventral spinal cords and met transgenic expression in cells
resembling MNs
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monitored the appearance and progression of motor defects
in SOD versus Nes-R26Met-SOD compared with controls by
employing swimming tank and footprint assays.27 Onset of
swimming defects was delayed by 14 days, as estimated by
the increased time that mice needed to execute this motor
task (SOD: 113±3 days; Nes-R26Met-SOD: 127±3 days;
P¼ 0.0015; Figure 8d), whereas disease progression was
unchanged (SOD: 30±3.9 days; Nes-R26Met-SOD: 22±2.7
days; P40.05; Figure 8e). Therefore, neuronal-enhanced
Met improved motor strength and swimming performance of
SOD mice by acting specifically on disease onset.
The motor capability of Nes-R26Met-SOD versus SODmice
was further evaluated by performing footprint studies (Sup-
plementary Figure 4). The forepaw/hindpaw overlap analysis
revealed a delay of 19 days in the locomotor gait dysfunction
(SOD: 108±3 days; Nes-R26Met-SOD: 127±3 days;
Figure 5 Subcellular localization of chimeric met transcripts in lumbar spinal
cords of adult Nes-R26Met mice. (a–c) Colocalization studies of exogenous met
transcript with NeuN protein showing met expression in neuronal cell types.
(d–f) Colocalization studies of exogenous met transcript with GFAP protein showing
that transgenic met is not predominantly expressed in astrocytes. Panels (b and e),
panels (c and f) correspond to an enlarged view of spinal cord areas indicated by
red and black rectangles in (a and b), respectively. Arrowheads in (c) point to MNs
co-expressing chimeric met transcript and NeuN protein. Arrows and arrowheads in
(f) indicate GFAP-positive astrocytes and MN expressing chimeric met transcripts,
respectively
Figure 4 Subcellular localization of the lacZ reporter gene in Nes-R26Met and
R26LacZstopMet mice. (a and b) Colocalization studies of X-Gal activity with NeuN
protein showing the reporter activity in neuronal cell types. (c and d) Enlarged view
of the hippocampus area. (e–h) Colocalization studies of X-Gal activity with GFAP
protein showing that the lacZ reporter gene is not predominantly expressed in
astrocytes. Panels (g and h) correspond to an enlarged view of the hippocampus.
(i–k) Mixed cell cultures derived from E12.5 R26LacZstopMet spinal cords were
immunostained for neurofilament-160 (red) and b-galactosidase (green) proteins.
(i–n) Astrocyte cultures from P2 R26LacZstopMet spinal cords immunostained for
GFAP (red) and b-galactosidase (green). DAPI was used to counterstain nuclei
(blue), scale bar: 20mm
Genetically enhancing Met levels in ALS neurons
M Genestine et al
6
Cell Death and Disease
P¼ 0.0009; Figure 8f), accompanied by a delay of 9 days in
the appearance of step-length defects (SOD: 106±2 days;
Nes-R26Met-SOD: 115±2 days; P¼ 0.0136; Figure 8h). The
motor performance decline rate was not appreciably different
betweenSOD andNes-R26Met-SODmice, showing that when
the disease has started, it progresses at the same rate
(overlap, SOD: 30±3.9 days; Nes-R26Met-SOD: 22±22.7
days; P40.05; step-length, SOD: 32±3.1 days; Nes-R26Met-
SOD: 34±1.7 days; P40.05; Figures 8g and i).
Neuronal-enhanced Met levels attenuate MN loss in
spinal cords of SOD mice. As motor performances were
transiently improved in Nes-R26Met-SOD mice by delaying
disease onset, we evaluated the neuroprotective effects of
increased Met levels by quantifying lumbar spinal cord MNs.
For these studies, we selected three animals among the
Nes-R26Met-SOD, SOD, and controls at the symptomatic
disease phase (120 days). This stage was chosen because
all behavioural studies showed significant differences
between groups. Lumbar spinal cord sections were stained
with VAChT antibodies and MN numbers were determined
(Figures 9a–c and m). As expected, we observed a
significant 60% MN loss in SOD mice compared with
controls (P¼ 0.0065). By contrast, neuronal-enhanced Met
in Nes-R26Met-SOD mice led to an improvement of MN
maintenance as the surviving MN numbers increased by
32% compared with SOD (P¼ 0.0002; Figure 9m).
We next assessed to what extent enhancing Met function in
neurons influenced astrogliosis and microglia activation,
which appear at disease onset and become more prominent
during progression.9 In contrast to controls, activated
GFAP-positive astrocytes (changes in fluorescence intensity)
were detected in lumbar spinal cords, although reduced
in Nes-R26Met-SOD compared with SOD (SOD: 15.5±
1.9 108; Nes-R26Met-SOD: 9.9±1.4 108; P¼ 0.0164;
Figures 9d–f and n). Similarly, the number of microglial cells
was reduced in Nes-R26Met-SOD mice compared with SOD
(SOD: 281.7±14.6; Nes-R26Met-SOD: 222.1±15.5;
P¼ 0.0016; Figures 9g–i and o). Analysis of muscle innerva-
tion revealed that the increased MN numbers in Nes-R26Met-
SOD was accompanied by an enhanced integrity of neuro-
muscular junctions (NMJs; SOD: 16±1.8%; Nes-R26Met-
SOD: 41.7±11.4%; P¼ 0.041; controls: 84.4±7.9%;
Figure 9p). Thus, increased neuronal Met levels elicit a
combination of protective effects in different cell types: (1) cell-
autonomous protective effects on spinal cord MNs and for
NMJ maintenance; (2) non-cell-autonomous delay of astro-
cyte activation and increased microglia cell numbers.
Discussion
Most of neurodegenerative diseases result from a combina-
torial action of pathological signals produced by neurons
themselves and by neighbouring cells acting in a non-cell-
autonomous manner.7 A number of molecules including
trophic factors and their receptors can elicit beneficial effects
on disease-related cells when applied in vitro and/or when
delivered in disease animal models. Understanding how these
Figure 6 Tissue-distribution of activated chimeric Met in adult brains and spinal cords. (a and b) Sagittal sections of adult brains showing phospho-Met staining in
Nes-R26Met, but not in R26LacZstopMet mice. (c–h) Enlarged view of phospho-Met distribution in the lateral ventricle (c), pons (d), cervical spinal cord (e), corresponding to
regions indicated by squares in panel (a). Distribution of phospho-Met in the hippocampus (f), olfactory bulb (g), and lumbar spinal cord (h). Arrowheads in (e and h) point to
phospho-Met-positive cells with large nuclei resembling MNs. cb, cerebellum; cc, cerebral cortex; lv, lateral ventricle; ob, olfactory bulb; p, pons; sc, spinal cord
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molecules act on dysfunctional cells remains a key topic to
clarify disease mechanisms and to evaluate their use for
therapies. We show here that enhanced signalling by Met has
an impact on a specific stage of ALS pathology when it is
selectively upregulated in neurons. Indeed, transgene-
mediated neuronal expression of Met elicits a beneficial
effect in SOD1G93A by delaying disease onset, but not
progression.
Our results are based on a genetic approach involving the
generation of conditional mettg mice, in which Met signalling
levels is modulated in a temporally and spatially regulated
manner. Such an approach offers the possibility of exploring
how enhanced Met signalling above endogenous levels
influences cell fate in developmental events, in adult
physiology, and in pathological conditions. Loss of Met
function during development interferes with identity acquisi-
tion, axonal growth, and survival of MN subsets.2,17–20 We
show here that neuronal-enhanced Met signalling levels do
not affect either MN development or function in adulthood,
whereas it influences MN maintenance in ALS pathological
conditions. Thus, it is likely that excessive Met functions are
restrained by mechanisms such as tissue homeostasis or by
limiting amounts of ligand. Importantly, the dispensable
function of Met in several adult tissues is in contrast to its
requirement in counteracting degenerative processes follow-
ing injuries, such as axotomy,21,22 hepatectomy,28 and skin-
wound.29 These regenerative studies together with our
findings indicate that in a pathological context, cell types like
neurons become sensitive to the beneficial effects provided
by Met. The generation of compound transgenics by crossing
the R26LacZstopMet mice with available cre-lines will offer a
unique genetic setting for determining tissue-specific sensi-
tiveness to enhanced Met signalling either during develop-
ment, in adulthood, or in pathologies.
The pleiotropic functions elicited by the HGF/Met system in
neurons have boosted the interest in exploring its potential for
Figure 7 Molecular and functional characterization of Nes-R26Met mice versus
controls. (a–f) Transversal sections through lumbar spinal cords showing similar
numbers of VAChT-positive (a–d) and GFAP-positive (e and f) cells. (g and h)
Quantification studies showed no significant difference in numbers of VAChT-
immunopositive cells (g; P40.05) and GFAP-fluorescence intensity (h; P40.05)
among the two groups of mice (n¼ 3). (i) Rotarod behavioural analysis in
Nes-R26Met and control littermate mice showing that enhanced neuronal Met levels
did not significantly influence locomotor performance (P40.05; n¼ 10). (j) Body
weight analysis in Nes-Mettg and control mice showed no significant differences
overtime. Body weight is expressed as weight evolution compared with that of mice
at age 77 days. Values are expressed as means±S.E.M.
Figure 8 Neuronal-enhanced Met signalling levels in ALS mice improves survival and locomotor performance by delaying disease onset. (a) Survival analysis of
Nes-R26Met-SOD (red) and SOD (green) mice (n¼ 40) showing a delay of 13 days of average life span. (b) The loss of 10% body weight was 13 day delayed in Nes-R26Met-
SOD (n¼ 11) compared with SOD (n¼ 17) mice. (c) Body weight loss was not significantly different in Nes-R26Met-SOD compared with SOD mice once the disease started
(P40.05). (d and e) Motor performance analysis using a 1 meter swimming tank device. Panel (d) shows a delay of 14 days in motor defect onset of Nes-R26Met-SOD mice
(n¼ 11) compared with SOD transgenics (n¼ 17). Panel (e) shows the analysis of the duration of locomotor defects with not significant differences between groups
(P40.05). (f–i) Comparison of motor performance using the footprint test. Analysis of the forepaw/hindpaw overlap revealed a 19 day improvement in Nes-R26Met-SOD mice
(n¼ 11) compared with SOD transgenics (n¼ 17; f). No significant differences were found during disease progression (g; P40.05). Step length defects also appeared with a
delay of 9 days in Nes-R26Met-SOD compared with SOD mice (h). Again, no changes were found during disease progression (i; P40.05). a, b, d, f and h are Kaplan–Meier
curves. Values are expressed as means±S.E.M.
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Figure 9 Effects of enhanced Met signalling in MN maintenance and astrogliosis at ALS symptomatic phase (120 days). (a–c) VAChT-stained sections through the ventral horn of
the lumbar spinal cord showed an increase in MN maintenance in Nes-R26Met-SOD compared with SOD transgenics. (d–f) GFAP-stained sections through the ventral horn of the
lumbar spinal cords showing astrogliosis inNes-R26Met-SOD andSODmice. (g–i) Iba-1-stained sections through the ventral horn of the lumbar spinal cords showing an increase in the
number of microglial cells in Nes-R26Met-SOD and SOD mice. (j–l) Immunofluorescence staining of gastrocnemius muscle with a-bungarotoxin-tetramethylrhodamine (red), anti-
neurofilament (green). Scale bar 50mm. (m) Quantification of MN numbers (VAChT-positive) among the three groups of mice, showing a 32% increase in Nes-R26Met-SOD compared
with SOD mice (Nes-R26Met-SOD versus SOD : P¼ 0.0002; SOD versus control: Po0.0001; Nes-R26Met-SOD versus control: P¼ 0.006; n¼ 3). (n) Quantification of fluorescence
intensity of GFAP-immunopositive cells. Significant differences were observed between the three groups (Nes-R26Met-SOD versus SOD : P¼ 0.0164; SOD versus control:
P¼ 0.0002; Nes-R26Met-SOD versus control: P¼ 0.0084; n¼ 3). (o) Quantification of Iba-1-positive cells. Significant differences in microglia numbers were observed between the
three groups (Nes-R26Met-SOD versus SOD : P¼ 0.0016; SOD versus control and Nes-R26Met-SOD versus control: Po0.0001; n¼ 3). (p) The percentage of a-Bungarotoxin-
stained end-plates showing complete or partial colocalization with neurofilament staining was evaluated in the three groups (Nes-R26Met-SOD versus SOD: P¼ 0.0416; controls
versus SOD : P¼ 0.0143; controls versus Nes-R26Met-SOD : P¼ 0.0256). Values are expressed as means±S.E.M. ***Po0.001, **Po0.01, *Po0.05
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ALS therapy through several strategies. HGF intrathecal
administration at disease onset provided evidence that, when
present at high doses and accessible to different disease
cells, HGF/Met attenuates MN degeneration and retards
disease progression by 11 days.30 However, these studies did
not clarify whether, and to what extent, the HGF/Met system
exerts support on MNs in a cell-autonomous manner. Insights
to this issue come from studies based on genetic neuronal
delivery of HGF in the low copy number SOD1G93A mice. In
particular, hgf expression driven by the neuron-specific
enolase-promoter delayed disease onset by approximately
28 days, rather than influencing its progression.23 However,
as exogenous HGF is expressed and secreted by neurons,
these hgf transgenic mice did not allow discriminating
between the HGF effects on MNs versus those elicited on
astrocytes, which in turn influence MNs and microglia
function. Consistently, a decrease in the number of microglia,
reactive astrocytes, and MN loss was observed in hgf
transgenics. Our mouse model allowed discrimination
between the cell-autonomous effects elicited by enhanced
Met signalling in MNs and those influenced by HGF on other
dysfunctional cells. Moreover, the Nes-R26Met mice estab-
lished that Met signalling in MNs selectively counteracts ALS
disease onset. It remains to be investigated what contribution
enhanced Met signalling, above endogenous levels in
astrocytes and microglia, could have with respect to disease
evolution.
The severity of ALS and the lack of effective therapeutic
strategies are driving efforts to explore agents, applied either
separately or in combination, to counteract disease symp-
toms. Concerning trophic factors, HGF could offer therapeutic
advantages at multiple levels. It is noteworthy that endogen-
ous Met is upregulated starting from ALS onset in ventral
spinal cords of SOD1G93A mice (data not shown and see Sun
et al.23). These observations indicate that endogenous Met is
turned on to counteract ALS symptoms, but endogenous
HGF levels may not be sufficient to reverse the damage, as
was found studying regeneration after optic-nerve axotomy
(unpublished results). Moreover, as HGF/Met elicits functions
in muscle cells,31,32 it is possible that ectopic HGF in muscles
would also counteract neuro-muscular-junction denervation
and muscle atrophy. Indeed, HGF favours the formation of
NMJs during development.33 Although enhanced Met activa-
tion is often associated with tumour formation andmetastasis,
we did not observe side effects such as neoplasia in
Nes-R26Met mice despite Mettg expression levels in regions
of the nervous system. Thus, the beneficial effects of HGF/
Met on ALS degenerative processes appear to be well
tolerated in healthy nervous system tissues.
The use of the conditional ALS mouse model, in which the
mutant SOD1 gene can be deleted according to the
cre-transgenic line used, has been instrumental in clarifying
the influence of distinct cell types during ALS evolution. In
particular, selective reduction of mutant SOD1 in MNs
predominantly impacts on disease onset and its early phase.
In contrast, reduced mutant SOD1 either in astrocytes or in
microglia mainly influences the late stage of disease progres-
sion.8,9 Thus, although recombination in Nes-R26Metmice did
not occur in 44% of lumbar spinal cord MNs, rebalancing the
levels of stress and survival signals and/or protecting
presynaptic terminals in ALS MNs, either by providing RTK
support (our studies), or by removing signals such as BAX
influencing NMJ integrity,12 or by depleting mutant SOD,8,9
ameliorates ALS by selectively delaying disease onset. It is
known that the initial MN damage is followed by a progressive
increase in cytotoxic and inflammatory mediator levels, which
further affect MN themselves and neighbouring cells. Astro-
cytes and microglia are the predominant cell types driving
disease progression towards death. Although disease pro-
gression is unchanged in Nes-R26Met mice, our genetic
analysis show that enhanced-neuronal Met in SOD mice
impacts on distinct cell types involved in the ALS disease:
MNs, in a cell-autonomous manner, possibly by providing
trophic support and/or maintenance of NMJ integrity and
astrocytes and microglia, in a non-cell-autonomous manner,
by delaying their activation. Future studies will establish the
relative contribution of each individual event in delaying the
onset of the disease by neuronal Met signalling and uncover
the underlying mechanisms.
Understanding how therapeutic reagents act at cellular
levels is needed to accelerate the progress of promising
treatments towards the clinic. Our findings emphasize the
relevance of genetically assessing the effects of agents on
distinct cell types implicated in a disease and during its
evolution. Although successful therapies for ALS will possibly
require concomitant actions on distinct dysfunctional cells, our
results highlight the considerable therapeutic potential of
modulating RTK signalling in MNs to combat degenerative
signals.
Materials and Methods
Generation of R26LacZstopMet mice. The R26LacZstopMet mice were
generated by taking advantage of the loxP-flanked (‘floxed’)-stop cassette system.
To generate the chimeric mouse–human gene, the human Met cDNA encoding the
transmembrane and cytoplasmic portion was fused in-frame with the mouse
extracellular cDNA sequence using the PvuII site present in both sequences. We
chose such a strategy to ensure that the Met chimeric protein interacts efficiently
with the endogenous mouse HGF, but can still be identified from the endogenous
mouse Met protein. The fusion product was subsequently subcloned into the
pCALL2 vector downstream of the insert containing the CMV enhancer-chicken
b-actin promoter followed by the loxP-flanked b-geo/3xpA cassette. This vector is
referred to as pCALL-Met. To generate the Rosa26 targeting construct, the insert
containing the CMV-enhancer/chicken-b-actin-promoter-loxP-flanked b-geo/3xpA-
Met was subcloned into the XhoI site of pRosa-1 vector previously modified using a
poly-linker. The targeting vector was electroporated into R1 ES cell lines. Cell
culture, electroporation, selection, and Southern blot analyses were performed as
previously described.32 To identify recombined clones, genomic DNA was digested
with EcoRI or EcoRV and probed with an external or internal probe, respectively.
Two selected ES cell lines carrying the homologous recombination were used to
generate the R26LacZstopMet mice through blastocyst injections.
Transgenic mice. The mouse line expressing cre recombinase under the
nestin promoter was previously described.25 The B6SJL-Tg(SOD1*G93A)
1Gur(SOD1G93A (SOD1G93A) mouse line was used as ALS disease model.34
Both R26LacZstopMet and nestin-cre mice were backcrossed into the B6SJL
genetic background before breeding with the SOD1G93A transgenics. The number of
mice used for behavioural and immuno-histochemical studies are indicated in figure
legends. Each genetic group consisted of a mixed population of equal numbers of
males and females. The presence of a vaginal plug in the morning was considered
as 0.5 embryonic day (E0.5). All procedures involving the use of animals were
performed in accordance with the European Community Council Directive of 24
November 1986 on the protection of animals used for experimental purposes
(86/609/EEC). The experimental protocols were carried out in compliance with
institutional ethical committee guidelines for animal research. All efforts were made
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to minimize the number of animals used and their suffering. When paralysis started,
food and water were placed directly into the cage. To reduce animal pain, mice were
killed when they were unable to right themselves within 30 s when placed on their
back.
Antibodies. Antibodies used were anti-tubulin and anti-GFAP and anti-VAChT
(1 : 1000; Sigma-Aldrich, St. Louis, MO, USA), anti-MetKD (1 : 1000) and anti-
phospho Y1234-1235-Met (1 : 50; Cell Signaling, Danvers, MA, USA), anti-human
Met (1 : 500; Santa-Cruz Biotechnology Inc., Santa Cruz, CA, USA), anti-Smi32
(1 : 500; Sternberger monoclonals, Covance, Dallas, TX, USA), anti-NeuN (1 : 200;
Chemicon, Millipore, Billerica, MA, USA), and anti-neurofilament-145 (1 : 1000;
AB1987; Millipore), anti-mouse or rabbit fluorescent-coupled secondary antibodies
(1 : 400; Jackson, West Grove, PA, USA), anti-mouse or rabbit biotin-coupled
secondary antibodies (1 : 500; Jackson). For western blot analyses, the following
secondary antibodies were used: anti-rabbit IgG-peroxidase or anti-mouse IgG-
peroxidase (1 : 4000, Jackson).
Histological analysis. Anesthetized mice were intra-cardiacally perfused first
with PBS then with 4% para-formaldehyde (PFA, Sigma) in PBS. Brains, spinal
cords, and muscles were dissected, postfixed in 4% PFA and embedded. For brain
and spinal cords, 16 or 30-mm thick cryo-sections were performed (Leica, Wetzlar,
Germany). In situ hybridization, immuno-histochemistry, and X-Gal staining were
performed as previously described.27,35,36 MN numbers were determined on 16-mm
thick lumbar spinal cord sections stained with VAChT antibodies or cresyl violet.
A total of 10 sections per mouse were analyzed. Astrogliosis was monitored by
measuring fluorescence-levels of sections stained with anti-GFAP antibodies
(Image J software, ImageJ 1.41, NIH, Bethesda, MD, USA). For NMJ staining,
35-mm thick longitudinal sections were collected on Superfrost Plus Slides
(CML, Thermo Scientific, Braunscheweig, Germany). Tissue sections were
incubated in blocking solution (0.5% Triton X-100, 5% BSA in PBS) at 37 1C for
2 h. Rabbit polyclonal anti neurofilament-145 antibodies were diluted in the same
blocking solution and incubated overnight at 4 1C. Anti-rabbit-alexa 488-conjugated
secondary antibody (Invitrogen, Life Technologies, Carlsbad, CA, USA) and
a-bungarotoxin-tetramethylrhodamine-conjugate (1 : 1000; Invitrogen) were
incubated for 2 h at room temperature (1% BSA in PBS), before washing and
mounting. Stained end-plates on sections were examined under an Axio
microscope (Zeiss, Oberkochen, Germany). Innervated (yellow) or denervated
(red) end-plates were counted on apoptome (Zeiss) 35-mm Z-stacks.
Biochemical studies. Protein extracts were prepared from freshly dissected
brains and spinal cords at the appropriate stages and western blot analyses were
performed as previously described.37–39 Quantifications were done by measuring
band intensities with the Image J software.
Cultures. Cell culture procedures were previously described.40 Briefly, E12.5
spinal cords from R26LacZstopMet transgenic embryos were dissected in Hank’s
Balanced Salt Solution containing 7 mM HEPES pH7.4 and 4.5 g/l glucose. Cells
were dissociated in Ham-F10 medium (Invitrogen) with 0.025% Trypsin (Sigma) and
centrifuged over a 4% (w/v) BSA cushion at 800 g for 5 min. Cells were plated on
poly-ornithine/laminin-treated coverslips in supplemented Neurobasal medium
(Invitrogen) containing neurotrophic factors (0.1 ng/ml GDNF, 1 ng/ml BDNF, and
10 ng/ml CNTF) and maintained at 37 1C in 7.5% CO2 atmosphere for 3 days before
being processed for immunochemistry. Astrocytes were prepared from P2
R26LacZstopMet spinal cords. When confluent, cells were trypsinized and plated
onto coverslips in Dulbecco’s modified Eagle’s (DMEM, Invitrogen) medium
supplemented with 10% fetal bovine serum and penicillin–streptomycin. Cells were
then cultured at 37 1C in 5% CO2 atmosphere for 3 days before immunostaining.
Cultured cells were processed for immunocytochemistry as above described. We
used the following primary antibodies diluted in PBS containing 4% BSA, 2%
donkey serum: anti-b-Gal (1 : 4000; Cappel, MP Biomedicals, Ullkirch, France), anti-
neurofilament 160 (1 : 600; NN18, Sigma), anti-GFAP (1 : 500; MAB360, Millipore).
Alexa Fluor 488 (1 : 500; A21206; Invitrogen) and 555 (1 : 1000; A31570;
Invitrogen)-conjugated donkey anti-rabbit and anti-mouse were used as
secondary antibodies (Invitrogen).
Behavioural tests. Body weight measurements and all behavioural tests
began when mice reached the age of 70 days and recording was performed weekly.
To analyze motor functions, locomotor tests included the rotarod, the 1 m swimming
tank and the footprint, which have been done as previously described.27 We
performed four trials at each time point for each animal and recorded the three best
performances for statistical analysis. Briefly, the rotarod test was performed by
placing mice on an accelerating rod (3 cm diameter) and by recording the time each
animal took to fall from the rod. The speed of the rotarod accelerated from 4 to
40 r.p.m. over a 5-min period. The swimming tank device allows evaluation of the
hindlimb strength and performance; it is suitable for assessing onset and
progression of ALS symptoms. For the swimming tank, each mouse performed four
trials and the time needed to reach the platform was recorded. A mouse was
considered at the onset of motor defect when it needed 6.8 s to perform the
swimming tank test. The 6.8 s were chosen as reference as this value corresponds
to the first significant difference versus control mice. For the footprint test, the fore-
toes and the hind-toes were labelled in blue and red, respectively. Weekly
monitoring of walking patterns allows assessment of motor coordination and
synchrony through the evaluation of several parameters, including toe spread,
forepaw/hindpaw overlap, and step-length. Two parameters were measured: (1) the
overlap distance between forepaw and hindpaw on the same side; (2) the stride
length as the distance of the hindpaw on the same side between each step. For the
overlap, the Kaplan–Meier curve indicates the mice when the distance between
forepaw and hindpaw increased by 45%. For the step length, the Kaplan–Meier
curve indicates when the distance of the hindpaw for each step decreased by 40%.
To reduce mouse stress and fatigue, the swimming and the footprint behavioural
tests were carried out on different days.
Statistical analysis. Results were expressed as the mean±S.E.M.
Statistically significant differences on cell counts were assessed by the Student’s
t-test. Statistically significant differences among the groups of mice were assessed
by two-way ANOVA. Post hoc Bonferroni’s correction was also used to test all pair-
wise comparisons between groups and time points per group. A log-rank test was
used to calculate the statistical differences in the onset and survival of the different
mouse cohorts. Statistical significance was defined as ns: P40.05; *Po0.05;
**Po0.01; ***Po0.001.
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